Rodrigo Andaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rodrigo Andaur has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ricardo Armisén
Centro de Genética y Genómica, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago 7550000, Chile
5 shared publications - Katherine Marcelain
Departamento de Oncología Básico Clínico, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile
3 shared publications - Sergio Davis
Research Center on the Intersection in Plasma Physics Matter and Complexity (P
3 shared publications B. Bora
Center for Research and Applications in Plasma Physics and Pulsed Power, P4
2 shared publicationsC. Pavez
Center for Research and Applications in Plasma Physics and Pulsed Power, P4
2 shared publicationsCésar Echeverría
Facultad de Medicina, Centro de Investigación y Tratamiento del Cáncer, Universidad de Chile, Chile
2 shared publications
Latest Publications
- 17 June 2026
- Published by Sociedad Chilena de Gastroenterología in Revista Gastroenterología Latinoamericana
- Vol. 37 (2) , 2-8
Efecto del consumo de tabaco sobre las manifestaciones asociadas a la intolerancia de la lactosa
La intolerancia a la lactosa (IL) es una condición gastrointestinal que impacta significativamente a los pacientes luego del consumo de alimentos que contienen lactosa. Sus síntomas, tales como diarrea, dolor abdominal, hinchazón y flatulencias, conllevan evitar los productos lácteos, resultando en una deficiencia nutricional. Alteraciones intestinales, aun en pacientes con persistencia de lactasa, pueden provocar síntomas similares a los descritos para pacientes con IL. El tabaquismo, conocido por alterar la microbiota intestinal, podría exacerbar la sintomatología clínica de la IL. Este estudio evaluó la relación entre el consumo de tabaco y las sintomatologías gastrointestinales en 67 estudiantes y funcionarios de la Universidad del Desarrollo (Santiago, Chile) en 2025. Para confirmar la IL, se realizó una genotipificación del polimorfismo LCT-13910C>T mediante qPCR y se aplicaron encuestas clínicas. Los resultados mostraron un predominio del genotipo C/C (49,3%), asociado significativamente a síntomas. Los fumadores presentaron una mayor frecuencia de síntomas (73,3%) comparado con no fumadores (67,5%), lo que asoció el consumo de tabaco a un mayor riesgo de manifestar la sintomatología de IL (OR > 1). Particularmente, el cigarro aumentó en 3,5 veces el riesgo de distensión abdominal (OR: 3,54, IC 95%: 0,93 – 13,51). Adicionalmente, el sexo femenino fue el predictor más robusto en la autopersepción de síntomas (p=0,005, OR: 7,90, IC 95%: 2,02 – 38,61).
- 17 June 2026
- Published by Sociedad Chilena de Gastroenterología in Revista Gastroenterología Latinoamericana
- Vol. 37 (2) , 2-8
Efecto del consumo de tabaco sobre las manifestaciones asociadas a la intolerancia de la lactosa
La intolerancia a la lactosa (IL) es una condición gastrointestinal que impacta significativamente a los pacientes luego del consumo de alimentos que contienen lactosa. Sus síntomas, tales como diarrea, dolor abdominal, hinchazón y flatulencias, conllevan evitar los productos lácteos, resultando en una deficiencia nutricional. Alteraciones intestinales, aun en pacientes con persistencia de lactasa, pueden provocar síntomas similares a los descritos para pacientes con IL. El tabaquismo, conocido por alterar la microbiota intestinal, podría exacerbar la sintomatología clínica de la IL. Este estudio evaluó la relación entre el consumo de tabaco y las sintomatologías gastrointestinales en 67 estudiantes y funcionarios de la Universidad del Desarrollo (Santiago, Chile) en 2025. Para confirmar la IL, se realizó una genotipificación del polimorfismo LCT-13910C>T mediante qPCR y se aplicaron encuestas clínicas. Los resultados mostraron un predominio del genotipo C/C (49,3%), asociado significativamente a síntomas. Los fumadores presentaron una mayor frecuencia de síntomas (73,3%) comparado con no fumadores (67,5%), lo que asoció el consumo de tabaco a un mayor riesgo de manifestar la sintomatología de IL (OR > 1). Particularmente, el cigarro aumentó en 3,5 veces el riesgo de distensión abdominal (OR: 3,54, IC 95%: 0,93 – 13,51). Adicionalmente, el sexo femenino fue el predictor más robusto en la autopersepción de síntomas (p=0,005, OR: 7,90, IC 95%: 2,02 – 38,61).
- 26 October 2021
- Published by AIP Publishing in Journal of Applied Physics
- Vol. 130 (16) , 164902
Hyper-radiosensitivity in tumor cells following exposure to low dose pulsed x-rays emitted from a kilojoule plasma focus device
In the present work, a kilojoule plasma focus device, PF-2 kJ, is adopted as a pulsed x-ray source to study the effects of pulsed radiation in cancer cells. Low dose hyper-radiosensitivity (LDHRS) effects have been explored in various cancer cell lines using conventional x-ray irradiation. To the best of our knowledge, the LDHRS effects have not yet been explored using pulsed x-rays. Cell death was evaluated in human colorectal (DLD-1 and HCT-116) and breast (MCF-7) cancer cell lines (monolayer cell cultures) irradiated with 10 (∼0.24 Gy), 20 (0.61 Gy), and 40 (∼1.1 Gy) pulses (FWHM ∼ 90 ns, dose rate ∼107 Gy/min with a dose of 0.025 Gy per pulse). The LDHRS cell death effect in the DLD-1 cell line irradiated with pulsed x-ray is three times higher than the reported for a conventional continuous x-ray source at two times higher doses. LDHRS was also observed in HCT-116 and MCF-7 cells exposed to 10 and 20 x-ray pulses, respectively, which are reported not to exhibit LDHRS when conventional continuous x-ray sources are used. Besides, a normal colorectal cell line, CCD-841-CoN, does not show a significant cell death at 10 pulses. These preliminary results suggest a selective effect of low-dose pulsed x-rays on cancer cells. The present work demonstrates the applicability of plasma focus devices for cancer research. Further possibilities in the exploration of pulsed x ray of high-dose rate and low total dose in radiotherapy research are opened.
- 26 October 2021
- Published by AIP Publishing in Journal of Applied Physics
- Vol. 130 (16) , 164902
Hyper-radiosensitivity in tumor cells following exposure to low dose pulsed x-rays emitted from a kilojoule plasma focus device
In the present work, a kilojoule plasma focus device, PF-2 kJ, is adopted as a pulsed x-ray source to study the effects of pulsed radiation in cancer cells. Low dose hyper-radiosensitivity (LDHRS) effects have been explored in various cancer cell lines using conventional x-ray irradiation. To the best of our knowledge, the LDHRS effects have not yet been explored using pulsed x-rays. Cell death was evaluated in human colorectal (DLD-1 and HCT-116) and breast (MCF-7) cancer cell lines (monolayer cell cultures) irradiated with 10 (∼0.24 Gy), 20 (0.61 Gy), and 40 (∼1.1 Gy) pulses (FWHM ∼ 90 ns, dose rate ∼107 Gy/min with a dose of 0.025 Gy per pulse). The LDHRS cell death effect in the DLD-1 cell line irradiated with pulsed x-ray is three times higher than the reported for a conventional continuous x-ray source at two times higher doses. LDHRS was also observed in HCT-116 and MCF-7 cells exposed to 10 and 20 x-ray pulses, respectively, which are reported not to exhibit LDHRS when conventional continuous x-ray sources are used. Besides, a normal colorectal cell line, CCD-841-CoN, does not show a significant cell death at 10 pulses. These preliminary results suggest a selective effect of low-dose pulsed x-rays on cancer cells. The present work demonstrates the applicability of plasma focus devices for cancer research. Further possibilities in the exploration of pulsed x ray of high-dose rate and low total dose in radiotherapy research are opened.
- 17 May 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 34 (10) , 1851-1861
Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway
Renal transplantation (RTx) is an effective therapy to improve clinical outcomes in paediatric patients with terminal chronic kidney disease. However, chronic immunosuppression with glucocorticoids (GC) reduces bone growth and mineral density. The mechanisms causing GC‐induced growth impairment have not been fully clarified. Fibroblast growth factor 23 (FGF23) is a peptide hormone that regulates phosphate homeostasis and bone growth. In pathological conditions, FGF23 excess or abnormal FGF receptors (FGFR) activity leads to bone growth impairment. Experimental data indicates that FGF23 expression is induced by chronic GC exposure. Therefore, we hypothesize that GC impairs bone growth by increasing FGF23 expression, which has direct effects on bone growth plate. In a post‐hoc analysis of a multicentric randomized clinical trial of prepubertal RTx children treated with early GC withdrawal or chronic GC treatment, we observed that GC withdrawal was associated with improvement in longitudinal growth and bone mineral density, and lower plasma FGF23 levels as compared to chronic GC group. In prepubertal rats, GC‐induced bone growth retardation correlated with increased plasma FGF23 and bone FGF23 expression. Additionally, GC treatment decreased FGFR1 expression while increased FGFR3 expression in mouse tibiae explants. Blockage of FGF23 receptors using a pan‐FGFR antagonist (PD173074), C‐terminal FGF23 (FGF23180‐205) which blocks the binding of FGF23 with FGFR‐Klotho complex or a specific FGFR3 antagonist (P3), prevented GC‐induced growth impairment in vitro. Finally, local administration of PD173074 into tibiae growth plate of GC‐treated rats ameliorated cartilage growth impairment. These results show that GC treatment partially reduces longitudinal bone growth via upregulation of FGF23 and FGFR3 expression, thus suggesting that the FGF23/Klotho/FGFR3 axis at the growth plate could be a potential therapeutic target for the management of GC‐induced growth impairment in children.
- 17 May 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 34 (10) , 1851-1861
Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway
Renal transplantation (RTx) is an effective therapy to improve clinical outcomes in paediatric patients with terminal chronic kidney disease. However, chronic immunosuppression with glucocorticoids (GC) reduces bone growth and mineral density. The mechanisms causing GC‐induced growth impairment have not been fully clarified. Fibroblast growth factor 23 (FGF23) is a peptide hormone that regulates phosphate homeostasis and bone growth. In pathological conditions, FGF23 excess or abnormal FGF receptors (FGFR) activity leads to bone growth impairment. Experimental data indicates that FGF23 expression is induced by chronic GC exposure. Therefore, we hypothesize that GC impairs bone growth by increasing FGF23 expression, which has direct effects on bone growth plate. In a post‐hoc analysis of a multicentric randomized clinical trial of prepubertal RTx children treated with early GC withdrawal or chronic GC treatment, we observed that GC withdrawal was associated with improvement in longitudinal growth and bone mineral density, and lower plasma FGF23 levels as compared to chronic GC group. In prepubertal rats, GC‐induced bone growth retardation correlated with increased plasma FGF23 and bone FGF23 expression. Additionally, GC treatment decreased FGFR1 expression while increased FGFR3 expression in mouse tibiae explants. Blockage of FGF23 receptors using a pan‐FGFR antagonist (PD173074), C‐terminal FGF23 (FGF23180‐205) which blocks the binding of FGF23 with FGFR‐Klotho complex or a specific FGFR3 antagonist (P3), prevented GC‐induced growth impairment in vitro. Finally, local administration of PD173074 into tibiae growth plate of GC‐treated rats ameliorated cartilage growth impairment. These results show that GC treatment partially reduces longitudinal bone growth via upregulation of FGF23 and FGFR3 expression, thus suggesting that the FGF23/Klotho/FGFR3 axis at the growth plate could be a potential therapeutic target for the management of GC‐induced growth impairment in children.
- 21 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (3) , 2037-2050
TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines
Transient Receptor Potential Melastatin 4 (TRPM4) is a Ca2+‐activated and voltage‐dependent monovalent cation channel, which depolarizes the plasma cell membrane, thereby modulating Ca2+ influx across Ca2+‐permeable pathways. TRPM4 is involved in different physiological processes such as T cell activation and the migration of endothelial and certain immune cells. Overexpression of this channel has been reported in various types of tumors including prostate cancer. In this study, a significant overexpression of TRPM4 was found only in samples from cancer with a Gleason score higher than 7, which are more likely to spread. To evaluate whether TRPM4 overexpression was related to the spreading capability of tumors, TRPM4 was knockdown by using shRNAs in PC3 prostate cancer cells and the effect on cellular migration and invasion was analyzed. PC3 cells with reduced levels of TRPM4 (shTRPM4) display a decrease of the migration/invasion capability. A reduction in the expression of Snail1, a canonical epithelial to mesenchymal transition (EMT) transcription factor, was also observed. Consistently, these cells showed a significant change in the expression of key EMT markers such as MMP9, E‐cadherin/N‐cadherin, and vimentin, indicating a partial reversion of the EMT process. Whereas, the overexpression of TRPM4 in LnCaP cells resulted in increased levels of Snail1, reduction in the expression of E‐cadherin and increase in their migration potential. This study suggests a new and indirect mechanism of regulation of migration/invasion process by TRPM4 in prostate cancer cells, by inducing the expression of Snail1 gene and consequently, increasing the EMT.
- 21 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (3) , 2037-2050
TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines
Transient Receptor Potential Melastatin 4 (TRPM4) is a Ca2+‐activated and voltage‐dependent monovalent cation channel, which depolarizes the plasma cell membrane, thereby modulating Ca2+ influx across Ca2+‐permeable pathways. TRPM4 is involved in different physiological processes such as T cell activation and the migration of endothelial and certain immune cells. Overexpression of this channel has been reported in various types of tumors including prostate cancer. In this study, a significant overexpression of TRPM4 was found only in samples from cancer with a Gleason score higher than 7, which are more likely to spread. To evaluate whether TRPM4 overexpression was related to the spreading capability of tumors, TRPM4 was knockdown by using shRNAs in PC3 prostate cancer cells and the effect on cellular migration and invasion was analyzed. PC3 cells with reduced levels of TRPM4 (shTRPM4) display a decrease of the migration/invasion capability. A reduction in the expression of Snail1, a canonical epithelial to mesenchymal transition (EMT) transcription factor, was also observed. Consistently, these cells showed a significant change in the expression of key EMT markers such as MMP9, E‐cadherin/N‐cadherin, and vimentin, indicating a partial reversion of the EMT process. Whereas, the overexpression of TRPM4 in LnCaP cells resulted in increased levels of Snail1, reduction in the expression of E‐cadherin and increase in their migration potential. This study suggests a new and indirect mechanism of regulation of migration/invasion process by TRPM4 in prostate cancer cells, by inducing the expression of Snail1 gene and consequently, increasing the EMT.
- Open Access
- 25 June 2018
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1043 (1) , 012047
In vitro irradiation of colorectal cancer cells by pulsed radiation emitted from a hundred joules plasma focus device and its comparison with continuous irradiation
In the last years, pulsed reduced low dose radiation has been proposed as an alternative for treatment of recurrent cancer. Nonetheless, distinction between the effects of low dose pulsed and continuous radiation is barely known at cellular level. In order to study the effects of low dose pulsed radiation at cellular level, in vitro experiments are important to further advance the basic understanding in this area. In the present work we demonstrate the usefulness of a low-energy plasma focus device PF-400J as a potential source of low-dose pulsed radiation for in vitro cancer cell experiments. Colorectal cancer cell line, DLD-1, were irradiated by pulsed x-rays. Fifty pulses of x-rays provide ~0.12 Gy dosis, which were measured using thermoluminescence detectors (TLD-100 dosimeters). Irradiation-induced DNA damage was assessed at different time points after irradiation. A statistically significant double strand break (DSB) DNA damage was observed at 30 minutes after irradiation. A comparison of DSB induced by continuous source in the same type cancer cells and pulsed irradiation is made at 30 minutes post-irradiation. In the case of pulsed irradiation, DSB per unit dose found higher. Our findings suggest that low-energy plasma focus devices could have potential application as pulsed radiation source in the area of in vitro cancer cell experiments.
- 25 June 2018
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1043 (1) , 012047
Open AccessIn vitro irradiation of colorectal cancer cells by pulsed radiation emitted from a hundred joules plasma focus device and its comparison with continuous irradiation
In the last years, pulsed reduced low dose radiation has been proposed as an alternative for treatment of recurrent cancer. Nonetheless, distinction between the effects of low dose pulsed and continuous radiation is barely known at cellular level. In order to study the effects of low dose pulsed radiation at cellular level, in vitro experiments are important to further advance the basic understanding in this area. In the present work we demonstrate the usefulness of a low-energy plasma focus device PF-400J as a potential source of low-dose pulsed radiation for in vitro cancer cell experiments. Colorectal cancer cell line, DLD-1, were irradiated by pulsed x-rays. Fifty pulses of x-rays provide ~0.12 Gy dosis, which were measured using thermoluminescence detectors (TLD-100 dosimeters). Irradiation-induced DNA damage was assessed at different time points after irradiation. A statistically significant double strand break (DSB) DNA damage was observed at 30 minutes after irradiation. A comparison of DSB induced by continuous source in the same type cancer cells and pulsed irradiation is made at 30 minutes post-irradiation. In the case of pulsed irradiation, DSB per unit dose found higher. Our findings suggest that low-energy plasma focus devices could have potential application as pulsed radiation source in the area of in vitro cancer cell experiments.
- Open Access
- 29 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (41) , 26387-26405
Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells
Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells “Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells”
- 29 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (41) , 26387-26405
Open AccessDifferential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells
Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells “Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells”
- 1 January 2018
- Published by Frontiers Media SA in Acta Virologica
- Vol. 62 (03) , 310-325
Time-course of transcriptome response to respiratory syncytial virus infection in lung epithelium cells
Time-course of transcriptome response to respiratory syncytial virus infection in lung epithelium cells
- 1 January 2018
- Published by Frontiers Media SA in Acta Virologica
- Vol. 62 (03) , 310-325
Time-course of transcriptome response to respiratory syncytial virus infection in lung epithelium cells
Time-course of transcriptome response to respiratory syncytial virus infection in lung epithelium cells
- Open Access
- 30 December 2017
- Published by Wiley in Molecular Oncology
- Vol. 12 (2) , 151-165
TRPM4 regulates Akt/GSK3‐β activity and enhances β‐catenin signaling and cell proliferation in prostate cancer cells
Increased expression of the TRPM4 channel has been reported to be associated with the progression of prostate cancer. However, the molecular mechanism underlying its effect remains unknown. This work found that decreasing TRPM4 levels leads to the reduced proliferation of PC3 cells. This effect was associated with a decrease in total β‐catenin protein levels and its nuclear localization, and a significant reduction in Tcf/Lef transcriptional activity. Moreover, TRPM4 silencing increases the Ser33/Ser37/Thr41 β‐catenin phosphorylated population and reduces the phosphorylation of GSK‐3β at Ser9, suggesting an increase in β‐catenin degradation as the underlying mechanism. Conversely, TRPM4 overexpression in LNCaP cells increases the Ser9 inhibitory phosphorylation of GSK‐3β and the total levels of β‐catenin and its nonphosphorylated form. Finally, PC3 cells with reduced levels of TRPM4 showed a decrease in basal and stimulated phosphoactivation of Akt1, which is likely responsible for the decrease in GSK‐3β activity in these cells. Our results also suggest that the effect of TRPM4 on Akt1 is probably mediated by an alteration in the calcium/calmodulin‐EGFR axis, linking TRPM4 activity with the observed effects in β‐catenin‐related signaling pathways. These results suggest a role for TRPM4 channels in β‐catenin oncogene signaling and underlying mechanisms, highlighting this ion channel as a new potential target for future therapies in prostate cancer.
- 30 December 2017
- Published by Wiley in Molecular Oncology
- Vol. 12 (2) , 151-165
Open AccessTRPM4 regulates Akt/GSK3‐β activity and enhances β‐catenin signaling and cell proliferation in prostate cancer cells
Increased expression of the TRPM4 channel has been reported to be associated with the progression of prostate cancer. However, the molecular mechanism underlying its effect remains unknown. This work found that decreasing TRPM4 levels leads to the reduced proliferation of PC3 cells. This effect was associated with a decrease in total β‐catenin protein levels and its nuclear localization, and a significant reduction in Tcf/Lef transcriptional activity. Moreover, TRPM4 silencing increases the Ser33/Ser37/Thr41 β‐catenin phosphorylated population and reduces the phosphorylation of GSK‐3β at Ser9, suggesting an increase in β‐catenin degradation as the underlying mechanism. Conversely, TRPM4 overexpression in LNCaP cells increases the Ser9 inhibitory phosphorylation of GSK‐3β and the total levels of β‐catenin and its nonphosphorylated form. Finally, PC3 cells with reduced levels of TRPM4 showed a decrease in basal and stimulated phosphoactivation of Akt1, which is likely responsible for the decrease in GSK‐3β activity in these cells. Our results also suggest that the effect of TRPM4 on Akt1 is probably mediated by an alteration in the calcium/calmodulin‐EGFR axis, linking TRPM4 activity with the observed effects in β‐catenin‐related signaling pathways. These results suggest a role for TRPM4 channels in β‐catenin oncogene signaling and underlying mechanisms, highlighting this ion channel as a new potential target for future therapies in prostate cancer.
- Open Access
- 1 August 2017
- Published by AIP Publishing in AIP Advances
- Vol. 7 (8) , 085121
Hundred joules plasma focus device as a potential pulsed source for in vitro cancer cell irradiation
Plasma focus devices may arise as useful source to perform experiments aimed to study the effects of pulsed radiation on human cells in vitro. In the present work, a table top hundred joules plasma focus device, namely “PF-400J”, was adapted to irradiate colorectal cancer cell line, DLD-1. For pulsed x-rays, the doses (energy absorbed per unit mass, measured in Gy) were measured using thermoluminescence detectors (TLD-100 dosimeters). The neutron fluence and the average energy were used to estimate the pulsed neutron doses. Fifty pulses of x-rays (0.12 Gy) and fifty pulses of neutrons (3.5 μGy) were used to irradiate the cancer cells. Irradiation-induced DNA damage and cell death were assessed at different time points after irradiation. Cell death was observed using pulsed neutron irradiation, at ultralow doses. Our results indicate that the PF-400J can be used for in vitro assessment of the effect of pulsed radiation in cancer cell research.
- 1 August 2017
- Published by AIP Publishing in AIP Advances
- Vol. 7 (8) , 085121
Open AccessHundred joules plasma focus device as a potential pulsed source for in vitro cancer cell irradiation
Plasma focus devices may arise as useful source to perform experiments aimed to study the effects of pulsed radiation on human cells in vitro. In the present work, a table top hundred joules plasma focus device, namely “PF-400J”, was adapted to irradiate colorectal cancer cell line, DLD-1. For pulsed x-rays, the doses (energy absorbed per unit mass, measured in Gy) were measured using thermoluminescence detectors (TLD-100 dosimeters). The neutron fluence and the average energy were used to estimate the pulsed neutron doses. Fifty pulses of x-rays (0.12 Gy) and fifty pulses of neutrons (3.5 μGy) were used to irradiate the cancer cells. Irradiation-induced DNA damage and cell death were assessed at different time points after irradiation. Cell death was observed using pulsed neutron irradiation, at ultralow doses. Our results indicate that the PF-400J can be used for in vitro assessment of the effect of pulsed radiation in cancer cell research.